CINCINNATI, OHIO, July 25: Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its Alethia® CMV assay. The addition of CMV expands Meridian’s existing Alethia menu, which includes C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian’s molecular diagnostic offerings in the Canadian market.
The Alethia platform delivers accurate molecular results in less than an hour to support evidence-based clinical decisions. With a small footprint and simple workflow, Alethia helps labs run efficiently while delivering reliable molecular results. The platform uses LAMP technology (loop-mediated isothermal amplification) for a cost-effective molecular solution.
With the Alethia CMV assay, Meridian delivers highly sensitive molecular detection with rapid turnaround time. Nearly 1 in 4 women carry cytomegalovirus (CMV), the most common congenital infection transmitted from mother to baby during pregnancy.1,2 Every year 1 in 200 babies are born with congenital CMV, and yet, the majority of pregnant women have never heard of it.3 Alethia CMV enables early detection of congenital CMV, which is vital in guiding appropriate clinical care for newborns. Congenital CMV testing empowers physicians and families with a full understanding of their newborn’s health prior to leaving the hospital.
“We are excited about the expanded menu offering of CMV on our Alethia platform in Canada. This allows Meridian to provide an important diagnostic solution for customers in the Canadian market. By utilizing saliva as the sample type, the assay delivers an easy-to-collect specimen for congenital CMV testing,” said Michelle Bosch, Vice President of Global Marketing. “The Alethia CMV assay provides clinicians with a valuable tool to aid in the diagnosis of congenital CMV.”